An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Apalutamide (Primary) ; LHRH receptor modulators (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 14 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Aug 2024.
- 14 Mar 2024 Status changed from not yet recruiting to recruiting.
- 17 Aug 2021 New trial record